Philadelphia, Pennsylvania–(Newsfile Corp. – June 29, 2023) – Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) NASDAQ: BTAI.

INVESTORS OF BIOXCEL STOCK WHO HAVE SUFFERED SIGNIFICANT FINANCIAL LOSSES ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C.

On June 29, 2023, Reuters reported that “BioXcel Therapeutics said on Thursday its experimental drug to treat agitation related to Alzheimer’s disease met the main goal in a late-stage study, but the results were marred by concerns over data integrity at one of the trial sites.”

Reuters also reported that “BioXcel said the principal investigator at the site was found to have fabricated email correspondence related to the timing of reporting serious side-effects to the company’s vendor responsible for monitoring safety of the drug so as to make it appear as though they had been reported in a timely manner as required by the trial protocol.”

On this news, shares of BioXcel stock were down more than 63% during intraday trading on June 29, 2023.

BIOXCEL SHAREHOLDERS WHO HAVE SUFFERED LOSSES OF $100,00 OR MORE ARE ALSO ENCOURAGED TO CONTACT EITHER JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, JKEHOE@KEHOELAWFIRM.COM, OR MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, MYARNOFF@KEHOELAWFIRM.COM, INFO@KEHOELAWFIRM.COM, TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.

Kehoe Law Firm, P.C. is a multidisciplinary, plaintiff-side law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm, P.C. have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion on behalf of institutional and individual investors.

This press release may constitute attorney advertising.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/171847